Strengths

High current and quick ratios indicate near-term liquidity resilience versus many small-cap medtech peers, reducing refinancing pressure despite weak profitability.

Low debt-to-equity and modest net debt to EBITDA suggest balance-sheet leverage is contained relative to more indebted peers, supporting financial flexibility.

The company’s capital structure appears less stretched than peers with heavier leverage, which can preserve optionality during prolonged commercialization cycles.

Negative ROIC remains a weakness, but the absence of severe leverage partly offsets it versus peers that combine losses with tighter liquidity.

Weaknesses

Negative TTM ROIC indicates capital is not generating returns, leaving NSPR structurally behind profitable peers on value creation.

A cash conversion cycle above 124 days ties up working capital, which is materially worse than peers with faster inventory and receivables turnover.

Missing operating and gross margin disclosure in the provided metrics limits visibility, but the available return profile still signals weak operating efficiency versus peers.

Despite adequate liquidity, the company’s low-return profile suggests commercialization remains less efficient than stronger medtech peers over a multi-year horizon.

Opportunities

If management shortens the cash conversion cycle, working-capital release could improve funding efficiency versus peers with slower inventory monetization.

The relatively strong liquidity position provides room to support product development and commercialization longer than peers facing tighter cash constraints.

Lower leverage than many peers could allow more strategic flexibility if execution improves, because incremental capital needs would be less constrained.

Any improvement in returns on invested capital would have outsized impact from the current low base, potentially narrowing the gap with better-positioned peers.

Threats

Persistent negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest more efficiently and compound market share.

A long cash conversion cycle increases working-capital drag, leaving NSPR more exposed than peers to demand volatility and execution slippage.

If commercialization remains slow, the company may continue to lag peers on margin expansion and capital efficiency, limiting structural positioning.

Small-cap medtech peers with stronger profitability and faster cash generation can outspend NSPR on growth, widening the competitive gap over time.

Overall Score

NSPR’s balance sheet is comparatively liquid and lightly levered, but persistent negative returns and slow working-capital turnover leave its structural positioning weaker than peers.